Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 2/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164883 | 0.90 | BACE1 (0.56) | HDAC1BACE1HDAC2HDAC3NCOR2 | |
| SCHEMBL396451 | 0.84 | BACE1 (0.65) | HDAC1BACE1APPHDAC2HDAC3 | |
| SCHEMBL29922357 | 0.84 | BACE1 (0.65) | HDAC1BACE1APPHDAC2HDAC3 | |
| SCHEMBL10353248 | 0.84 | BACE1 (0.44) | HDAC1BACE1APPHDAC2HDAC3 | |
| SCHEMBL19278371 | 0.82 | TAAR1 (0.47) | HDAC1HDAC2KDM4EALDH1A1KMT2A | |
| SCHEMBL17177679 | 0.81 | MEN1 (0.68) | HDAC1BACE1HDAC2HDAC3NCOR2 | |
| SCHEMBL95038 | 0.81 | MAPT (0.55) | HDAC1BACE1APPHDAC2HDAC3 | |
| SCHEMBL11019341 | 0.81 | MAPT (0.55) | HDAC1BACE1APPHDAC2HDAC3 | |
| SCHEMBL17605132 | 0.81 | MAOB (0.55) | HDAC1KCNH3KDM4EMEN1ALDH1A1 | |
| SCHEMBL15722540 | 0.81 | HDAC1 (0.43) | HDAC1BACE1HDAC2HDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402880-A1 | BICYCLIC INHIBITORS OF CBX CHROMODOMAINS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-22 | — | — | US | disclosed |
| US-11077107-B2 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2021-08-03 | — | — | US | disclosed |
| WO-2021061801-A1 | BICYCLIC INHIBITORS OF CBX CHROMODOMAINS | ICAHN SCHOOL OF MEDICINE AT MT. SINAI (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20190240219-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-10328074-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| EP-2925761-B1 | TRIAZOLOPYRAZINES AS BRD4 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2017-07-05 | — | — | EP | disclosed |
| CN-105218537-B | Berberine benzimidazole compounds or pharmaceutically acceptable salts thereof as well as preparation methods and applications of berberine benzimidazole compounds or pharmaceutically acceptable salts of berberine benzimidazole compounds | 西南大学 | 2017-01-11 | — | — | CN | disclosed |
| US-20160129001-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160129001-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20140142098-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-5461059-A | Antihistamine; treats allergies and asthma | LABORATOIRE THERAMEX S.A. (FR) | 1995-10-24 | — | — | US | disclosed |
| EP-0505543-A1 | NOVEL p-SUBSTITUTED PHENYL 4-OXYBUTANE AMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LABORATOIRE THERAMEX (MC) | 1992-09-30 | — | — | EP | disclosed |
| US-5151424-A | Antiallergens or antihistamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-09-29 | — | — | US | disclosed |
| EP-0297661-B1 | [(Bicyclic heterocyclyl)methyl and -hetero] substituted hexahydro-1H-azepines and pyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-09-16 | — | — | EP | disclosed |
| WO-1992006977-A1 | NOVEL p-SUBSTITUTED PHENYL 4-OXYBUTANE AMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LABORATOIRE THERAMEX S.A. (MC) | 1992-04-30 | — | — | WO | disclosed |
| US-5071846-A | Anti-hystaminic [(bicyclic heterocyclyl) methyl and --hetero] substituted hexahydro-1H-azepines and pyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-12-10 | — | — | US | disclosed |
| US-4988689-A | Antiallergens, antihistamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-01-29 | — | — | US | disclosed |
| EP-0297661-A1 | [(Bicyclic heterocyclyl)methyl and -hetero] substituted hexahydro-1H-azepines and pyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-04 | — | — | EP | disclosed |
| EP-0005318-B1 | N-HETEROCYCLYL-4-PIPERIDINAMINES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, INTERMEDIATES THEREFOR, AND METHOD FOR THE PREPARATION OF THE INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-01-06 | — | — | EP | disclosed |
| US-4219559-A | N-Heterocyclyl-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240219-A1 | TRIAZOLOPYRAZINE | MKI67, CCNI, CCNT2 | HDAC1 886/4885BACE1 3731/4885APP 3910/4885 |
| US-20160129001-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS | BRD4, BRD3, BICRA | HDAC1 22/4885BACE1 2869/4885APP 3621/4885 |
| US-20140142098-A1 | TRIAZOLOPYRAZINE | MKI67, CCNI, CCNT2 | HDAC1 886/4885BACE1 3731/4885APP 3910/4885 |
| US-10328074-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors | BRD4, BRD3, BICRA | HDAC1 22/4885BACE1 2869/4885APP 3621/4885 |
| US-11077107-B2 | Triazolopyrazine | MKI67, CCNI, CCNT2 | HDAC1 886/4885BACE1 3731/4885APP 3910/4885 |
| US-20220402880-A1 | BICYCLIC INHIBITORS OF CBX CHROMODOMAINS | CBX2, CBX3, CBX7 | HDAC1 216/4885BACE1 3985/4885APP 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.